BIODEXA PHARMACEUTICALS PLC

Press Releases Biodexa Pharmaceuticals Plc

Equities

BDRX

US59564R7089

Market Closed - Nasdaq Other stock markets 16:00:00 2024-05-16 EDT			5-day change	1st Jan Change
1.24 ^USD	+9.73%		+24.04%	-53.73%

05:20pm	European Equities Traded in the US as American Depositary Receipts Trend Lower in Thursday Trading	MT
05-15	European Equities Traded in the US as American Depositary Receipts Nudge Higher in Wednesday Trading	MT

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Biodexa’s Licensor Emtora to Announce Phase 2 Clinical Trial Results of eRapa™ in Familial Adenomatous Polyposis to be Presented at Prestigious 2024 Digestive Disease Week Annual Meeting	04-30	AQ
Biodexa Enters Into Exclusive License to eRapa™, a Phase 3 Ready Asset for the Treatment of Familial Adenomatous Polyposis (FAP)	04-26	AQ
Preliminary Results for the Year Ended 31 December 2023	04-19	AQ
Biodexa Announces Positive Top Line Phase I Clinical Trial Results for Diffuse Midline Glioma and Provides R&D Update	02-23	AQ
Biodexa Reports 12 Month Survival in MAGIC-G1 Study of MTX110 in Recurrent Glioblastoma Patients	02-08	AQ
Biodexa Announces Allowance of U.S. Patent Covering Tolimidone	02-07	AQ
Biodexa CEO Issues Shareholder Letter Highlighting Progress in 2023 and Expected Milestones in 2024	01-22	AQ
Biodexa Appoints Ann Merchant to the Board of Directors	12-29	AQ
Biodexa Announces Closing Of $6.0 Million Underwritten Public Offering, Including Full Exercise Of Overallotment Option	12-21	AQ
Biodexa Announces Pricing of $5.2 Million Underwritten Public Offering	12-19	AQ
Biodexa Enters Into Agreements to Acquire Exclusive Worldwide License to Tolimidone, a Phase II Ready Asset for Type 1 Diabetes	11-27	AQ
Biodexa Completes Recruitment of Cohort A in Study of MTX110 in Patients with Recurrent Glioblastoma	23-10-03	AQ
Biodexa Pharmaceuticals : SUBMITTED HEREWITH - Form 6-K	23-09-29	PU
Biodexa to Present Recruitment and Treatment Update in Phase 1 Study of MTX-110 (MAGIC-G1 Study) in Patients with Recurrent Glioblastoma at 2023 Annual European Association of Neuro-Oncology Meeting (EANO)	23-09-21	AQ
Biodexa Pharmaceuticals Launches New Corporate and Clinical Trials Websites	23-07-28	AQ
Biodexa Regain Compliance with NASDAQ Minimum Bid Price Requirement	23-07-24	AQ
Midatech Pharma : Biodexa Pharmaceuticals PLC?Annual Report 2022Biodexa Pharmaceuticals PLC(formerly Midatech Pharma Plc)Annual Report 2022 - Form 6-K	23-06-01	PU
Midatech Pharma : Notice of 2023 AGM	23-05-21	PU
Midatech Pharma : Press release dated April 28, 2023 - Form 6-K	23-04-28	PU

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.

BENEFIT NOW